Viking Therapeutics (VKTX) Long-Term Debt Repayments (2017)
Viking Therapeutics' (VKTX) quarterly Long-Term Debt Repayments came in at $200000.0 in Q3 2017, up 100.0% quarter-over-quarter from $100000.0 in Q2 2017.
Viking Therapeutics (VKTX) Long-Term Debt Repayments (2017) Analysis & Trends
Viking Therapeutics has disclosed Long-Term Debt Repayments across 1 years of filings, most recently posting $200000.0 for Q3 2017.
- Long-Term Debt Repayments for Q3 2017 came in at $200000.0, changed N/A year-over-year; the trailing twelve-month figure through Dec 2018 was $200000.0 (down 33.33% YoY), and the FY2018 annual result was $3.8 million, up 4877.92% from the prior year.
- Long-Term Debt Repayments came in at $200000.0 for Q3 2017 at Viking Therapeutics, up from $100000.0 in the prior quarter.
- In the past five years, Long-Term Debt Repayments ranged from a high of $200000.0 in Q3 2017 to a low of $100000.0 in Q2 2017.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Repayments (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -21,671.00 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Viking Therapeutics | 3.50 Bn | 3.50 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2017 | 200,000.00 |
| Sep 30, 2017 | 200,000.00 |
| Jun 30, 2017 | 100,000.00 |
| Jun 30, 2017 | 100,000.00 |